Trial Profile
A randomized, double blind, 2-treatment, 2-period, single-dose, cross over, comparative study to evaluate pharmacokinetics, safety and tolerability of Stelis Teriparatide [rh-PTH (1-34)] [teriparatide, Stelis Biopharma Pvt. Ltd., India] with ForsteoRegistered Trademark (teriparatide, Eli Lilly Nederland BV, Grootslag 1-5, NL-3991 RA Houten, The Netherlands) in healthy volunteers following subcutaneous administration of a single dose of 20 mcg Teriparatide
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis; Skin disorders
- Focus Pharmacokinetics
- Sponsors Stelis Biopharma
- 12 Mar 2018 New trial record